This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: F84.2 | Special Copayment Reduction: V122 |
| B. Synonyms | Rett syndrome, RTT, MECP2-related Rett syndrome, typical Rett syndrome, atypical Rett syndrome (MECP2, CDKL5, FOXG1 variant types) |
| C. Adult onset | Unlikely to first appear in adulthood — onset in childhood (6–18 months of age), and initial diagnosis in early adulthood is rare |
| 1. History | First described by Andreas Rett of Austria in 1966, international description by Hagberg et al. in 1983, MECP2 gene identified in 1999 |
| 2. Causes | MECP2 gene (X-linked) mutation: loss of function of methyl-CpG binding protein 2 → widespread abnormalities of neural gene expression |
| 3. Genetics | X-linked dominant, MECP2 gene Xq28, mostly de novo mutations, 95% occur in girls, male carriers die in the neonatal period |
| 4. Epidemiology | 1 per 10,000–20,000 live female births, estimated about 350,000–400,000 worldwide; distributed worldwide without ethnic or regional differences |
| 5. Pathophysiology | Loss of MECP2 protein function → failure of methylated CpG binding and transcriptional repression → overexpression of many neural genes → impaired synaptic maturation and maintenance |
| 6. Symptoms | 4 stages: early stagnation stage → rapid regression stage (loss of hand function, hand-wringing stereotypies) → plateau stage → late motor deterioration stage |
| 7. Signs | Hand stereotypies (wringing, washing), breathing abnormalities (hyperventilation, apnea), seizures, scoliosis, lower limb rigidity, microcephaly (acquired) |
| 8. Screening | Developmental assessment (confirmation of regression), brain MRI (exclusion of structural lesions), EEG (epilepsy assessment), MECP2 gene testing performed first |
| 9. Diagnosis | Revised international diagnostic criteria (2010): 4 main criteria + supportive criteria, molecular confirmation by MECP2 gene testing |
| 10. Treatment | No curative treatment (clinical trials of curative gene therapy in progress); seizure management, respiratory support, spinal surgery, nutritional management, rehabilitation |
| 11. Prognosis | Survival to age 5: 97%; survival to age 25: about 78%, median age of survival 47 years or more; cardiorespiratory failure and aspiration pneumonia are the main causes of death |
| 12. Prevention | Mostly de novo mutations, so direct prevention is difficult; prenatal/preimplantation genetic diagnosis available for families at risk of recurrence |
| 13. References | Amir et al. Nat Genet 1999 and 9 other papers |
Rett syndrome originated in 1966 when Andreas Rett, a pediatrician in Vienna, Austria, observed two girls showing stereotypic hand-rubbing behavior in the same waiting room. Rett subsequently followed 22 girls with a similar clinical picture, described them as a distinct clinical syndrome, and published it in a German-language paper in 1966, but at the time it did not attract international attention.
It was only in 1983, when researchers from several countries, including the Swedish pediatric neurologist Bengt Hagberg, analyzed 35 cases in girls and published a systematic clinical description in English in an international journal, that it gained worldwide attention. Hagberg et al. named the syndrome 'Rett syndrome' and established its core clinical features, including regression after normal development, loss of purposeful hand use and hand stereotypies, breathing abnormalities, seizures, and loss of walking.
The molecular genetic cause was identified in 1999 when Amir et al. showed that mutations in the MECP2 (methyl CpG binding protein 2) gene cause Rett syndrome. MECP2 is located at Xq28 on the X chromosome and encodes an epigenetic regulatory protein that binds to methylated cytosine and regulates gene transcription. This discovery established Rett syndrome as a disease with a specific molecular mechanism caused by gene mutation, and atypical Rett syndrome variants due to other gene variants such as CDKL5 and FOXG1 were subsequently identified. A 2007 study by Bird et al. showed in a mouse model that restoring MECP2 function in adulthood can reverse symptoms, offering hope for the possibility of treatment.
More than 95% of typical (classic) Rett syndrome is caused by pathogenic mutations in the MECP2 (Methyl-CpG binding protein 2) gene located at Xq28 on the X chromosome. The MECP2 protein contains a methyl-CpG binding domain (MBD), which binds to methylated DNA CpG sequences, and a transcriptional repression domain (TRD), and functions as an epigenetic regulator that represses transcription of numerous neural genes through chromatin compaction.
Loss of MECP2 function results in overexpression of many neural genes that should normally be repressed, causing widespread impairment of synaptic development and maturation and neural circuit formation. MECP2 is one of the most abundantly expressed proteins in the brain, with particularly high expression in mature neurons. This characteristic explains why symptoms appear during postnatal brain maturation rather than in the fetal period.
Besides MECP2 mutations, variants in the CDKL5 (X-linked, early-onset seizure variant of atypical Rett syndrome) and FOXG1 (14q12, congenital Braga variant of atypical Rett syndrome) genes also show clinical features similar to the Rett syndrome phenotype, but these are classified as separate disease groups that are clinically and molecular-genetically distinct. MECP2 overexpression (duplication) syndrome is a separate disease that occurs mainly in boys due to X-chromosome duplication of the MECP2 region.
The MECP2 gene is located at the terminal end of the long arm of the X chromosome (Xq28) and consists of 4 exons. It is inherited in an X-linked dominant manner, and about 99% of patients with Rett syndrome are girls. This is because boys with an MECP2 mutation on their single X chromosome (hemizygous) have no functional MECP2 protein at all and die in the fetal or neonatal period or present with severe neonatal encephalopathy.
The reason Rett syndrome manifests in girls is the incompleteness of X-chromosome inactivation (lyonization). Normal girls randomly inactivate one of their two X chromosomes, so symptom severity can vary depending on the proportion of X chromosomes carrying the mutant MECP2 that are inactivated. If the mutant X chromosome is preferentially inactivated, symptoms are mild; in the opposite case, a more severe phenotype is seen.
About 99% of MECP2 mutations are de novo mutations, and rarely they are maternally transmitted. The main types of pathogenic mutations are missense mutations (8 major hotspots, R106W, R133C, T158M, R168X, R255X, R270X, R294X, R306C, etc., account for about 60–70% of the total), nonsense mutations, small deletions, and large deletions. The CDKL5 and FOXG1 genes also cause atypical Rett syndrome in an X-linked or autosomal manner.
Rett syndrome is the second most common cause of intellectual disability in girls, occurring at a frequency of 1 per 10,000–20,000 live female births. An estimated about 350,000–400,000 patients exist worldwide. The prevalence is observed to be similar in all populations worldwide, regardless of ethnicity or geographic location.
Because most cases (about 99%) are caused by de novo mutations, most have no family history. Rarely, familial cases are also reported in which a female carrier of a mutant MECP2 (with no or a mild phenotype) transmits it to her children. Because most are de novo mutations, the sibling recurrence risk is low, less than 1%, but the possibility of recurrence due to maternal germline mosaicism (gonadal mosaicism) (about 1%) cannot be excluded, so prenatal diagnosis is recommended in subsequent pregnancies.
In Korea, accurate domestic prevalence statistics are limited, but applying the international rate of 1 per 10,000–20,000 female births, a considerable number of patients are estimated to exist. Support organizations for patients with Rett syndrome are also active in Korea, and a genetic diagnosis system is in place.
The main function of the MECP2 protein is to bind to methylated DNA (CpG sequences) and repress transcription of the corresponding genes. MECP2 interacts with HDAC (histone deacetylase) complexes and NCoR (nuclear receptor corepressor) complexes to compact chromatin, thereby precisely regulating the expression of thousands of neural genes. Normally, it represses unnecessary gene expression during brain maturation, achieving optimization and stabilization of neural synapses.
When MECP2 function is lost, this transcriptional repression breaks down, and synapse-related genes, ion channel genes, growth factor-related genes, etc. are broadly and abnormally overexpressed. In particular, abnormalities in BDNF (brain-derived neurotrophic factor), DLX5/6, MeCP2-binding signaling pathways, etc. are being studied as important pathophysiological contributing factors. As a result, reduced dendritic arbor of cortical and brainstem neurons, decreased synaptic density, inhibitory-excitatory signaling imbalance, and dysfunction of respiratory control neurons occur, causing the neurological symptoms of Rett syndrome.
Dysfunction of the brainstem respiratory control center (particularly the pre-Bötzinger complex) has been shown to be the direct cause of the irregular breathing pattern characteristic of Rett syndrome (alternating hyperventilation and apnea). Dysfunction of thalamocortical networks explains sleep disturbances and seizure susceptibility, and autonomic dysfunction is associated with the risk of sudden death (SUDEP). In mouse models, it has been demonstrated that restoring MECP2 function even after reaching adulthood reversibly restores many symptoms, suggesting therapeutic potential even in adult patients.
The clinical course of Rett syndrome is divided into 4 characteristic stages.
Developmental stagnation begins, but symptoms are subtle and often not detected early. Decreased eye contact, reduced social interest, hypotonia, and slowed growth rate (deceleration of head growth) begin to appear. This period lasts from several months to more than 1 year.
This is the period when the most dramatic symptoms appear: over several weeks to months, previously acquired purposeful hand skills are lost, and characteristic stereotypies such as hand wringing, hand washing, and hand-to-mouth movements emerge. Language ability is also lost, and social withdrawal deepens. Irregular breathing (alternating hyperventilation and apnea, air swallowing) and epileptic seizures often begin during this period. Sleep disturbances and teeth grinding (bruxism) also appear.
This stage is characterized by stabilization of regression, some improvement in seizures, and partial recovery of eye contact. During this period, interest in the environment may increase somewhat and communication ability may improve slightly. Walking ability is often maintained.
Loss or marked decline of walking ability appears, and scoliosis progresses. Muscle rigidity, joint contractures, and lower limb weakness are prominent. Seizure frequency may decrease somewhat during this period. This stage persists for decades, and many patients survive into adulthood with appropriate support.
The main physical signs supporting the diagnosis in typical Rett syndrome are as follows. The most characteristic sign is hand stereotypies: conscious, purposeful hand use disappears, and repetitive movements such as wringing, squeezing, clapping, tapping, and washing appear continuously while awake. It is important on observation that the stereotypies disappear during sleep.
Breathing abnormalities are prominent in the awake state, with repeated hyperventilation and apnea and abdominal distension due to air swallowing. Breathing abnormalities may be accompanied by cardiac arrhythmias (QT interval prolongation), increasing the risk of sudden death. Seizures (epilepsy) occur in about 80% of patients and take various forms, including focal seizures, generalized seizures, and atypical absence seizures.
Acquired microcephaly: head circumference is normal at birth, but head growth slows from 3–12 months of age. Scoliosis occurs in more than 80% of patients and requires surgical correction when it progresses rapidly. Lower limb rigidity, pes cavus, and joint contractures are also common signs. Diffuse cerebral atrophy may be observed on brain MRI but is nonspecific, and the absence of structural lesions is typical. EEG may show reduced background activity, generalized slowing, and spike-and-slow-wave complexes.
Screening evaluation for Rett syndrome is started when developmental stagnation or regression is identified in a girl after 6–18 months of age. Developmental screening tools (DENVER II, K-ASQ, etc.) and checking the achievement of previous developmental milestones are the basic tools. In particular, loss of purposeful hand use, emergence of hand stereotypies, loss of language, and breathing abnormalities should be carefully asked about in the history.
MECP2 gene testing should be performed first when Rett syndrome is clinically suspected. The main exons (2, 3, 4) are analyzed by Sanger sequencing, and if negative, MLPA (multiplex ligation-dependent probe amplification) or array-CGH is performed to detect large exon deletions/duplications. When genetic testing is negative and clinical suspicion is high, additional testing of the CDKL5 and FOXG1 genes is considered.
Brain MRI is performed to exclude structural lesions, but usually only normal or nonspecific atrophic findings are observed. EEG is essential for determining the presence and type of seizures, and atypical EEG abnormalities aid differential diagnosis. Hearing testing is performed to exclude hearing loss, and electrocardiography to check for QT interval prolongation. Assessment of nutritional status (BMI, growth curves) and scoliosis (spinal X-ray) is also needed to establish baselines.
The clinical diagnosis of Rett syndrome follows the revised diagnostic criteria published by the international Rett syndrome criteria committee in 2010. For the diagnosis of typical (classic) Rett syndrome, all of the following main criteria must be met.
Main criteria: ① partial or complete loss of acquired purposeful hand skills ② partial or complete loss of spoken language ③ gait abnormalities (impaired gait or loss of walking) ④ emergence of characteristic hand stereotypies (hand wringing, hand squeezing, clapping, washing, mouthing) replacing intentional hand use. All four of these criteria must be met.
Exclusion criteria: neurological abnormalities due to prenatal·perinatal brain injury, severe metabolic disease or progressive neurodegenerative disease, and severe brain malformations must be excluded. Atypical Rett syndrome is diagnosed when 2–4 of the 4 main criteria are met and at least 2 of 5 supportive criteria are met.
Molecular genetic confirmation is made by identifying a pathogenic mutation in the MECP2 gene. When MECP2 testing is negative after the clinical criteria are met, CDKL5 or FOXG1 gene testing is considered. Even if an MECP2 variant is found, MECP2-related Rett syndrome cannot be confirmed unless the clinical criteria are met, so integrated clinical-molecular interpretation is important.
There is currently no clinically approved fundamental treatment (disease-modifying therapy) for Rett syndrome, but in 2023 trofinetide (Daybue) received US FDA approval as a treatment for Rett syndrome, becoming the first symptom-relieving drug. Trofinetide is a synthetic analog of IGF-1 that improves symptoms by improving synaptic function and suppressing neuroinflammation, and in the phase 3 trial (LAVENDER) it showed significant improvement on both the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Clinical Global Impression-Improvement (CGI-I).
Antiepileptic drugs (AEDs) are selected according to seizure type. Valproate, lamotrigine, and levetiracetam are mainly used, and combination therapy is needed for mixed patterns of multiple seizure types. Carbamazepine is effective for generalized seizures but may worsen some seizure types in Rett syndrome, so caution is needed. When cardiac QT interval prolongation is present, drug interactions must be considered when selecting an AED.
There is no established drug that directly treats the irregular breathing of Rett syndrome itself. QT prolongation and arrhythmias are tracked through ECG monitoring (Holter), and when QT prolongation is present, QT-prolonging drugs (certain antibiotics, antifungals, antihistamines, etc.) should be avoided. Consultation with a cardiologist is needed for severe bradycardia or arrhythmias.
The progression of scoliosis is tracked with regular radiographic examination (spinal X-ray every 6–12 months). Curve 20–40 degrees: use of bracing. Curve 40–50 degrees or more: surgical spinal correction and fusion considered. Early correction is important for preserving respiratory function.
Malnutrition due to dysphagia and gastrointestinal dysmotility is common, so regular nutritional assessment and caloric supplementation are needed. Feeding via nasogastric tube or gastrostomy (PEG) is sometimes needed. Calcium and vitamin D supplementation and weight-bearing exercise to prevent osteoporosis are important. Multidisciplinary rehabilitation including physical therapy, occupational therapy, speech therapy, and augmentative and alternative communication (AAC) is key to maintaining function and improving quality of life.
Rett syndrome is a very rare and serious disease, but life can be sustained for a considerable period. Survival to age 5 is reported at about 97%, and survival to age 25 at about 77–78%. The median age of survival is 47 years or more, and many patients survive into adulthood, some into their 60s–70s. The most common cause of death is respiratory failure due to aspiration pneumonia, followed by status epilepticus, sudden death due to autonomic dysfunction (SUDEP, sudden unexpected death in epilepsy), and cardiopulmonary complications.
The type of MECP2 mutation has a partial correlation with clinical severity. In general, R133C, R294X, and R306C are associated with relatively mild phenotypes, while R255X, R270X, R168X, and large deletions are associated with severe phenotypes. However, even among patients with the same mutation, severity differs depending on the X-chromosome inactivation pattern.
Rett syndrome is currently incurable, but through symptom management and rehabilitation, some patients can maintain a meaningful level of function. Several clinical trials targeting MECP2 gene therapy (viral vector-based) and restoration of MECP2 expression are in progress, and promising early results have been reported in some studies, so a change in the treatment paradigm is expected in the future.
Because about 99% of Rett syndrome is caused by de novo mutations, there is currently no way to predict or prevent onset when there is no family history. Families in which Rett syndrome has been diagnosed in the first child are informed of the recurrence risk in subsequent pregnancies (about 1% due to germline mosaicism) and offered prenatal diagnosis or preimplantation genetic testing (PGT-M).
In the rare cases where an MECP2 mutation is transmitted to children from a maternal carrier (a female carrier with no or mild symptoms), the recurrence risk reaches 50%, so genetic counseling and prenatal diagnosis are even more important in these families. Identification of a carrier mother is made through parental testing after molecular genetic testing of the confirmed patient.
Currently, newborn screening to prevent the onset of Rett syndrome is not standardized in most countries. Some studies have suggested that early diagnosis can advance the start of early intervention (rehabilitation, education) and improve functional outcomes, and with the decreasing cost of genetic testing, the possibility of inclusion in future newborn genetic screening is being discussed. Linkage to multidisciplinary specialist centers and access to patient and family support programs should be provided from an early stage.